What it's for (Indications)
- Cefoperazone, often administered in combination with sulbactam, is a broad-spectrum cephalosporin antibiotic indicated for the treatment of various serious bacterial infections caused by susceptible organisms.
- Its primary clinical uses encompass a wide range of conditions, including respiratory tract infections such as pneumonia and bronchitis, complicated urinary tract infections, and severe intra-abdominal infections like peritonitis, cholecystitis, and cholangitis.
- Furthermore, it is highly effective in treating septicemia, meningitis, skin and soft tissue infections, pelvic inflammatory disease, and other gynecological infections.
- Its utility extends to bacterial septicemia and infections of bones and joints, making it a valuable agent for managing severe nosocomial and community-acquired infections requiring parenteral antibiotic therapy.
- The specific indication for use should always be guided by local epidemiological data, clinical judgment, and confirmed susceptibility testing of the isolated pathogens to ensure optimal therapeutic outcomes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage regimen for cefoperazone (e.g., Nena-Zone) must be carefully individualized based on the severity and nature of the infection, the patient's renal and hepatic function, body weight, and the susceptibility of the causative pathogen. For adult patients, typical intravenous or intramuscular doses range from 2 to 4 grams per day, administered in equally divided doses every 12 hours. In cases of severe or refractory infections, such as those occurring in immunocompromised patients or involving highly resistant organisms, the daily dose may be increased up to a maximum of 12 grams, administered in 2 to 4 divided doses. For patients with impaired renal function, especially those with creatinine clearance less than 18 mL/min, dose adjustment is necessary, often requiring a reduction to 1-2 grams every 12 hours, with serum drug levels monitored if possible. Hepatic impairment may also necessitate dosage modification due to the primary biliary excretion of the drug, particularly when combined with renal insufficiency. Pediatric dosing must also be meticulously calculated based on body weight and clinical condition, typically ranging from 100-150 mg/kg/day in divided doses. |
Safety & Warnings
Common Side Effects
- As with any potent antibiotic, cefoperazone can elicit a range of side effects, although many are mild and transient.
- The most commonly reported adverse reactions involve the gastrointestinal system, including diarrhea, nausea, vomiting, and abdominal discomfort; *Clostridioides difficile*-associated diarrhea (CDAD) is a significant, albeit less common, risk.
- Hypersensitivity reactions are also frequent, manifesting as skin rashes, urticaria, pruritus, and drug fever; severe reactions like anaphylaxis, though rare, can be life-threatening and require immediate medical intervention.
- Hematologic abnormalities, particularly an increased tendency for bleeding, can occur due to inhibition of vitamin K synthesis, especially in patients with pre-existing risk factors such as malnutrition, malabsorption, or chronic liver disease; this can manifest as epistaxis, ecchymosis, or, in severe cases, hemorrhage.
- Other potential side effects include transient elevations in liver transaminases (AST, ALT), alkaline phosphatase, and bilirubin, indicating hepatic enzyme disturbance.
- Injection site reactions, such as pain, tenderness, or phlebitis, are common with intravenous administration.
- Superinfections, including candidiasis or overgrowth of other non-susceptible organisms, are also significant concerns that can arise from prolonged antibiotic use.
Serious Warnings
- Black Box Warning: Cefoperazone is not associated with an FDA-mandated Black Box Warning. However, several serious warnings merit significant attention during its administration, and these should be considered critical for patient safety. **Serious Warnings:** **1. Hypersensitivity Reactions:** Severe, life-threatening hypersensitivity reactions, including anaphylaxis, have been reported with cephalosporin antibiotics. Patients with a history of allergies, especially to penicillins, are at increased risk. Prior to initiation, a thorough allergy history must be taken. If an allergic reaction occurs, cefoperazone should be discontinued immediately, and appropriate emergency treatment instituted, including but not limited to epinephrine, antihistamines, and corticosteroids. **2. Bleeding Disorders (Coagulopathy):** Cefoperazone contains a methylthiotetrazole (MTT) side chain, which can lead to hypoprothrombinemia by interfering with vitamin K metabolism. This can result in an increased risk of bleeding, manifesting as ecchymosis, epistaxis, gastrointestinal bleeding, or more severe hemorrhage. Patients at higher risk include those with poor nutritional status, malabsorption syndromes, chronic liver disease, renal impairment, or those receiving concomitant anticoagulant therapy. Prophylactic administration of vitamin K may be necessary in these susceptible populations to mitigate the risk of coagulopathy. Close monitoring of prothrombin time (PT) and international normalized ratio (INR) is strongly recommended. **3. _Clostridioides difficile_-Associated Diarrhea (CDAD):** CDAD has been reported with nearly all antibacterial agents, including cefoperazone, and can range in severity from mild diarrhea to fatal colitis. It is crucial to consider CDAD in the differential diagnosis for patients presenting with diarrhea after antibiotic use, which may occur weeks after discontinuation. Prompt and accurate diagnosis followed by appropriate management, including discontinuation of cefoperazone if warranted and initiation of specific treatment for _C. difficile_, is essential. **4. Disulfiram-like Reaction with Alcohol:** Concurrent ingestion of alcohol or alcohol-containing products during or within 72 hours after cefoperazone administration can precipitate a disulfiram-like reaction (e.g., flushing, sweating, headache, nausea, vomiting, tachycardia, hypotension). Patients must be explicitly warned to avoid all forms of alcohol (including oral and parenteral products containing alcohol) during and for at least 3 days following completion of treatment with cefoperazone.
- Serious warnings associated with cefoperazone use necessitate careful patient monitoring and consideration.
- **Hypersensitivity Reactions:** Severe and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving cephalosporin therapy, including cefoperazone.
- Before initiating therapy, careful inquiry should be made concerning previous hypersensitivity reactions to cephalosporins, penicillins, or other allergens.
- If an allergic reaction occurs, the drug should be discontinued immediately, and appropriate emergency medical treatment (e.
- g.
- , epinephrine, antihistamines, corticosteroids) instituted.
- **_Clostridioides difficile_-Associated Diarrhea (CDAD):** CDAD has been reported with nearly all antibacterial agents, including cefoperazone, and may range in severity from mild diarrhea to fatal colitis.
- It is important to consider this diagnosis in patients who present with diarrhea following antibiotic administration, sometimes occurring up to two months post-therapy.
- **Bleeding Disorders:** Cefoperazone contains a methylthiotetrazole side chain, which can interfere with vitamin K metabolism, potentially leading to hypoprothrombinemia and an increased risk of bleeding.
- Patients with poor nutritional status, malabsorption syndromes, or impaired renal/hepatic function are particularly susceptible.
- Prophylactic vitamin K administration may be considered in these high-risk individuals, and close monitoring of coagulation parameters is recommended.
- **Disulfiram-like Reaction:** A disulfiram-like reaction, characterized by flushing, sweating, headache, and tachycardia, has been reported when alcohol is ingested during or within 72 hours of cefoperazone administration.
- Patients should be explicitly advised to avoid alcohol and alcohol-containing products during treatment and for several days post-treatment.
- **Development of Drug-Resistant Bacteria:** Prolonged use of cefoperazone may result in the overgrowth of non-susceptible organisms.
- Prescribing cefoperazone in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
How it Works (Mechanism of Action)
Cefoperazone is a bactericidal antibiotic belonging to the third-generation cephalosporin class. Its primary mechanism of action involves the inhibition of bacterial cell wall synthesis. The drug achieves this by covalently binding to and inactivating several essential enzymes known as penicillin-binding proteins (PBPs), which are located on the inner surface of the bacterial cytoplasmic membrane. These PBPs play a crucial role in the final stages of peptidoglycan synthesis, specifically the transpeptidation reaction, which is responsible for cross-linking the peptidoglycan strands to form a rigid and stable bacterial cell wall. By disrupting this critical process, cefoperazone weakens the cell wall, leading to increased osmotic pressure within the bacterial cell. This osmotic instability ultimately results in bacterial cell lysis and death, thereby exerting its potent bactericidal effect against a wide spectrum of susceptible Gram-positive and Gram-negative bacteria. When administered in combination with sulbactam, a potent beta-lactamase inhibitor, its spectrum of activity is significantly broadened, as sulbactam protects cefoperazone from hydrolytic degradation by many bacterial beta-lactamase enzymes, including those produced by _Staphylococcus aureus_ and various Gram-negative bacilli.